USPTO serial 79420148
STAB
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 28, 2026
- Examiner
- BROWN, TINA
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with STAB?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
ES
ES
ES
ES
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Bradley M. Stohry
Bradley M. Stohry Reichel Stohry Dean LLP6151 Central AveIndianapolis, IN 46220United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biological preparations for use in cell cultures for medical purposes; preparations for detecting genetic predispositions for medical purposes; diagnostic reagents for medical use; chemical reagents for medical use; biological reagents for medical use; cells for medical use; living cells for medical use; antibodies for medical purposes; cell growth media for growing cells for medical or clinical use; cellular function activating agents for medical purposes; anti-cancer preparations; biopharmaceuticals for the treatment of cancer; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; human and animal cells and related parts for medical use, namely, cell culture media for medical use, viral vectors, for medical use, namely, pharmaceutical preparations containing viral vectors for the treatment or prevention of cancer and immune-related diseases; chemical reagents for medical use, namely, lentiviruses, lentivirus particles and lentivirus plasmids, for medical use; therapeutic preparations and substances for gene and cell therapy for medical use, namely, pharmaceutical preparations for gene therapy and cell therapy for the treatment of cancer and immune-related diseases; gene therapy products, namely, genetically engineered tissues for transplant purposes; lentiviral vectors, for medical use, namely, pharmaceutical preparations containing lentiviral vectors for gene and cell therapy for the treatment of cancer and immune-related diseases; adeno-associated viral vectors, adenoviral vectors and non-viral vectors for the delivery of genes to cells for medical use, namely, pharmaceutical preparations for gene therapy for the treatment of cancer and immune-related diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention of diseases of the immune system; all the aforesaid goods expressly excluding substances and preparations for veterinary use; medicines and pharmaceuticals based on messenger RNA (mRNA) for the treatment of cancer and immune-related diseases; pharmaceutical and medicinal preparations for use in the field of targeting messenger RNA (mRNA) and triggering its degradation for the treatment of cancer and immune-related diseases; mRNA-based therapeutic preparations and therapeutic agents for the prevention and treatment in vivo, ex vivo and in situ of oncological diseases or tumors; pharmaceutical preparations consisting of messenger RNA and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells for the treatment of cancer and immune-related diseases | ACTIVE | — |
| 042 | Biological research; medical research services; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; gene therapy research; research and development in the field of microorganisms and cells; development of cell therapy products; product development in the field of immunotherapy; pharmaceutical drug development services in the field of cell therapy; pharmaceutical drug development services in the field of immunotherapy; development of gene-based medicines; design and development of medical technology in the field of cell therapy; design and development of medical technology in the field of immunotherapy; research and development of vaccines and medicines; consultancy relating to pharmaceutical research and development in the field of cell therapy; consultancy relating to pharmaceutical research and development in the field of immunotherapy; research and development services in the field of antibodies; research and development services in the field of gene expression systems; laboratory services relating to the production of monoclonal antibodies, namely, laboratory research services relating to pharmaceuticals and biotechnology; scientific services relating to the isolation and cultivation of human tissues and cells, namely, scientific research and scientific laboratory services; research and development services in the field of immunology; research and development services in the field of cell therapy; research and development services in the field of immunotherapy; research and development of mRNA drugs | ACTIVE | — |
| 045 | Licensing authority services in the field of cellular therapy, namely, patent licensing, trademark licensing; licensing authority services in the field of immunotherapeutics, namely, patent licensing, trademark licensing; licensing of technology, namely, patent licensing, trademark licensing; licensing of intellectual property | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by STAB THERAPEUTICS, S.L.
- Other trademarks owned by STAB THERAPEUTICS, S.L.
- Other trademarks owned by STAB THERAPEUTICS, S.L.
- Other trademarks owned by STAB THERAPEUTICS, S.L.U.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 045
- Similar marks named STAB
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 28, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Sep 10, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Aug 26, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 26, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jul 28, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 28, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 9, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 9, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 3, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 13, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 13, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 13, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 13, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 13, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 15, 2026 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Mar 15, 2026 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 15, 2026 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 12, 2026 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Feb 4, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 4, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 4, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 23, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 6, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 6, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 16, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 15, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 10, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 28, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 28, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 28, 2025 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Mar 27, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |